Arachnoiditis, Degenerative Disk Disease, Epidural Fibrosis, Failed Back Surgery Syndrome, Radiculopathies
Conditions
Brief summary
The purpose of this study is to evaluate the effect of different spinal cord stimulation settings in the treatment of leg pain. Subjects will receive a randomized order of four different programmed stimulation settings for 3 weeks each followed by a fifth and final setting.
Interventions
DEVICETherapy Setting 1 (Medtronic)
RestoreSensor or RestoreUltra Setting 1
DEVICETherapy Setting 2 (Medtronic)
Medtronic RestoreSensor or RestoreUltra Setting 2
DEVICETherapy Setting 3 (Medtronic)
Medtronic RestoreSensor or RestoreUltra Setting 3
DEVICETherapy Setting 4 (Medtronic)
Medtronic RestoreSensor or RestoreUltra Setting 4
Sponsors
MedtronicNeuro
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* At least 22 years of age or older at the time of informed consent * Implanted with a Medtronic RestoreSensor or RestoreUltra SCS system for an on-label indication at least 6 months for the treatment of chronic leg pain, with or without back pain * Implanted with one or more Medtronic leads located in the epidural space within the thoracic area * Receiving some level of pain relief with current SCS therapy * On a stable dose (no new, discontinued or changes in) of all prescription pain medications and willing to maintain or only decrease the dose of all prescribed pain medications * Read and understand English without assistance * Willing and able to comply with all study procedures, study visits, and be available for the duration of the study
Exclusion criteria
* Diagnosed with complex regional pain syndrome (CRPS), peripheral causalgia, or reflex sympathetic dystrophy (RSD), or causalgia * Has leg, knee, or foot pain unrelated to on-label indication for SCS therapy (for eg, arthritis, knee surgery, etc.) * Implanted with both a surgical and percutaneous lead * Implanted with a peripheral lead for subcutaneous or peripheral nerve stimulation * Has had any of the following procedures: * Neuroablative procedure within six months * Neurolytic block within two months * Injection therapy for pain within four weeks * Sympathetic block within two weeks * Has an active implanted device (besides RestoreUltra or RestoreSensor neurostimulator), whether turned ON or OFF * Pregnant or lactating, inadequate birth control, or at risk of pregnancy during this study * Has an untreated psychiatric comorbidity * Has serious drug-related behavioral issues * Has active malignancy or has been diagnosed with cancer and has not been in remission for at least one year * Has secondary gains which, in the opinion of the investigator, are likely to interfere with the study * Participating or planning to participate in another clinical trial while enrolled in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Numeric Pain Rating Scale - Leg pain | 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Brief Pain Inventory - Pain severity | 12 weeks |
| Brief Pain Inventory - Pain interference | 12 weeks |
| Quantitative Sensory Testing - Vibration threshold | 12 weeks |
| Quantitative Sensory Testing - Electrical stimuli tolerance | 12 weeks |
| Numeric Pain Rating Scale - Back pain | 12 weeks |
Outcome results
None listed